Statin Needs to be Continued During Paxlovid Therapy in COVID-19

To the Editor—We read with interest the study published by Najjar-Debbiny and co-authors [1]. This recent large population-based study was carried out in Israel among patients who were at high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and who had no contraindications for the use of Paxlovid. Very interestingly, those patients who benefitted the most from Paxlovid were those who had a preexisting cardiovascular (P = .028) or neurological disease (P = .016).

The authors emphasized that several drugs have been suggested as treatments of SARS-CoV-2 infection, but most of these measures have not effectively reduced the risk of progression to severe disease or are too expensive or logistically difficult to be used widely. As pointed out above, Paxlovid treatment was most beneficial among patients having a preexisting cardiovascular or neurological disease, and therefore being at high cardiovascular risk. The majority of these patients should have been treated with a statin to reduce their cardiovascular risk [2]. Simvastatin is a very frequently used statin as it is cheap and worldwide available. In the protocol of the study, the use of simvastatin was a contraindication for the use of Paxlovid, which accords with the information provided by the manufacturer of Paxlovid [3]. However, there are other statins like fluvastatin and pravastatin which can be safely used with Paxlovid to substitute for simvastatin during the critical early phase of severe SARS-CoV-2 infection [3].

Statins have been shown to improve the prognosis of severe SARS-CoV-2 infection [4]. So we argue that the ongoing use or introduction of statins needs to be taken into account when trying to prevent severe clinical consequences associated with a serious SARS-CoV-2 infection. For the physicians managing such patients, what needs to be emphasized is that statin therapy should not be discontinued and, in many cases, may need to be even intensified. This particularly applies to patients with severe hypercholesterolemia, such as those with familial hypercholesterolemia, who are at highly increased risk of coronavirus disease 2019 (COVID-19)–related vascular incidents including acute myocardial infarction and ischemic stroke [5, 6].

An additional very interesting view derives from the observation in animal models demonstrating that the SARS-CoV-2 main protease (M\textsuperscript{PRO}) adversely affects microvascular endothelial cells in the brain [7]. While Paxlovid is an inhibitor of the SARS-CoV-2 M\textsuperscript{PRO} [8] it has also been suggested that, at least in silico, statins could directly interact with the M\textsuperscript{PRO}, fluvastatin being one such example [9]. So from a theoretical point of view, dual inhibition of M\textsuperscript{PRO} could be accomplished by using Paxlovid together with fluvastatin. However, any added clinical benefit of such combination therapy needs to be confirmed in human studies. The other advantage of long-lasting statin therapy is that the inhibition of M\textsuperscript{PRO} would also last longer compared to the short period of Paxlovid therapy. This aspect is important to consider, especially because in some COVID-19 patients, the infection rebounds after stopping Paxlovid treatment [10].

Note
Potential conflicts of interest. A. V. reports support for attending meetings and/or travel for European Atherosclerosis Society (EAS) (EAS paid flight tickets and accommodation); and role as unpaid member of the editing team Finnish Current Guidelines in Dyslipidemia. P. T. K. has received consultancy fees, lecture honoraria, and/or travel fees from Amgen, Novartis, Raisio Group, and Sanofi. F. R. has received research grants, honoraria, or consulting fees for professional input and/or lectures from Sanofi, Regeneron, Amgen, and Novartis, and is a board member of the International Atherosclerosis Society, unpaid. The other author reports no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Alpo Vuorio,1,2* Petri T. Kovanen,3 and Frederick Raal1,2,4
1Mehiläinen Airport Health Centre, Vantaa, Finland; 2Department of Forensic Medicine, University of Helsinki, Helsinki, Finland; 3Wihuri Research Institute, Helsinki, Finland; and 4Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa

References
1. Najjar-Debbiny R, Gronich N, Weber G, et al. Effectiveness of Paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients. Clin Infect Dis 2022;ciaa443.
2. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies: 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk [published correction appears in Atherosclerosis]. 2020 Feb; 294:80-82. Atherosclerosis 2019; 290:140–205.
3. Vuorio A, Kovanen PT, Raal F. Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid therapy. Future Virol 2022. In press.
4. Talasaz AH, Sadeghipour P, Aghakouchakzadeh M, et al. Investigating lipid-modulating agents for prevention or treatment of COVID-19: JACC state-of-the-art review. J Am Coll Cardiol 2021; 78:1635–54.
5. Vuorio A, Strandberg TE, Raal F, Santos RD, Kovanen PT. Familial hypercholesterolemia and COVID-19: a menacing but treatable vasculopathic condition. Atheroscler Plus 2021; 433:3–6.
6. Vuorio A, Kaste M, Kovanen PT. Familial hypercholesterolemia and statins in the COVID-19 era: mitigating the risk of ischemic stroke. eNeurologicalSci 2021; 23:100344.
7. Wenzel J, Lampe J, Müller-Fiedlt H, et al. The SARS-CoV-2 main protease M\textsuperscript{PRO} causes microvascular brain pathology by cleaving NEMO in brain endothelial cells. Nat Neurosci 2021; 24:1522–33.
8. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 M\textsuperscript{PRO} inhibitor clinical candidate for the treatment of COVID-19. Science 2021; 374: 1586–93.
9. Reiner Z, Hatamipour M, Banach M, et al. Statins and the COVID-19 main protease: in silico evidence on direct interaction. Arch Med Sci 2020; 16:490–6.
10. Rubin R. From positive to negative to positive again—the mystery of why COVID-19 rebounds in some patients who take Paxlovid. JAMA 2022; 327:2380–2.

Correspondence: A. Vuorio, University of Helsinki, 00100 Helsinki, Finland, and Mehiläinen Airport Health Centre, 01500 Vantaa, Finland (alpo.vuorio@gmail.com).

Clinical Infectious Diseases®
© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
https://doi.org/10.1093/cid/ciac657